Literature DB >> 22251994

New technologies for influenza vaccines.

Philip R Dormitzer1, Theodore F Tsai, Giuseppe Del Giudice.   

Abstract

Influenza vaccine preparations have been administered to humans since the late 1930s, and the diversity of approaches in licensed trivalent seasonal or monovalent pandemic products is unparalleled by vaccines against any other target. These approaches include inactivated whole virus vaccines, detergent or solvent "split" vaccines, subunit vaccines, live attenuated vaccines, adjuvanted vaccines, intramuscular vaccines, intradermal vaccines, intranasal vaccines, egg-produced vaccines and mammalian cell culture-produced vaccines. The challenges of influenza immunization, including multiple co-circulating strains, antigenic change over time, a broad age spectrum of disease, and the threat of pandemics, continue to drive the development of new approaches. This review describes some of the new approaches to influenza immunization that are the subjects of active research and development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22251994     DOI: 10.4161/hv.8.1.18859

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  22 in total

1.  Cell-culture derived fowl adenovirus serotype 4 inactivated vaccine provides complete protection for virus infection on SPF chickens.

Authors:  Dongying Du; Pantao Zhang; Xiangdong Li; Hui Tian; Yi Cheng; Dongbei Sheng; Xueying Han; Yihong Shan; Xuefeng Li; Yue Yuan; Haiyang Zhang; Jingjing Xue; Wujie Liu; Kegong Tian
Journal:  Virusdisease       Date:  2017-05-10

Review 2.  Fast vaccine design and development based on correlates of protection (COPs).

Authors:  Cécile van Els; Siri Mjaaland; Lisbeth Næss; Julia Sarkadi; Eva Gonczol; Karen Smith Korsholm; Jon Hansen; Jørgen de Jonge; Gideon Kersten; Jennifer Warner; Amanda Semper; Corine Kruiswijk; Fredrik Oftung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Biomimetic antigenic nanoparticles elicit controlled protective immune response to influenza.

Authors:  Dustin P Patterson; Agnieszka Rynda-Apple; Ann L Harmsen; Allen G Harmsen; Trevor Douglas
Journal:  ACS Nano       Date:  2013-04-10       Impact factor: 15.881

Review 4.  Vaccine approaches conferring cross-protection against influenza viruses.

Authors:  Sai V Vemula; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Expert Rev Vaccines       Date:  2017-09-19       Impact factor: 5.217

5.  Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines.

Authors:  Larry R Smith; Walter Wodal; Brian A Crowe; Astrid Kerschbaum; Peter Bruehl; Michael G Schwendinger; Helga Savidis-Dacho; Sean M Sullivan; Mark Shlapobersky; Jukka Hartikka; Alain Rolland; P Noel Barrett; Otfried Kistner
Journal:  Hum Vaccin Immunother       Date:  2013-03-06       Impact factor: 3.452

6.  Preparation and evaluation of a novel, live, attenuated influenza H1N1 vaccine strain produced by a modified classical reassortment method.

Authors:  Yunfeng Long; Lei Ma; Ze Liu; Shaohui Song; Xingliang Geng; Fan Yang; Qi Guo; Zhuofan Li; Weidong Li; Guoyang Liao
Journal:  Hum Vaccin Immunother       Date:  2017-10-31       Impact factor: 3.452

Review 7.  Development of a universal CTL-based vaccine for influenza.

Authors:  Diego Esteban Cargnelutti; María Victoria Sánchez; Nora Marta Mattion; Eduardo Alberto Scodeller
Journal:  Bioengineered       Date:  2013-01-21       Impact factor: 3.269

8.  Production of avian influenza virus vaccine using primary cell cultures generated from host organs.

Authors:  Mustafeez Mujtaba Babar; Muhammad Suleman Riaz; Najam-us-Sahar Sadaf Zaidi; Farhan Afzal; Muhammad Sabir Farooq
Journal:  J Ind Microbiol Biotechnol       Date:  2013-03-21       Impact factor: 3.346

9.  Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge.

Authors:  Xiaolan Yang; Jianyu Zhao; Cheng Wang; Yueqiang Duan; Zhongpeng Zhao; Rui Chen; Liangyan Zhang; Li Xing; Chengcai Lai; Shaogeng Zhang; Xiliang Wang; Penghui Yang
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

Review 10.  Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Authors:  Elke S Bergmann-Leitner; Wolfgang W Leitner
Journal:  Vaccines (Basel)       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.